The tests of the Covid 19 vaccine from the Boston biotech company Moderna started the third and final clinical trial phase on Monday morning . The National Institutes of Health announced this on Monday.
At 6: 45 local time was in Savannah , Georgia, the first of about 30 in one of 89 testing centers across the United States. 000 subjects were vaccinated with the novel vaccine (or placebo).
[Jetzt noch mehr wissen: Mit Tagesspiegel Plus können Sie viele weitere spannende Geschichten, Service- und Hintergrundberichte lesen. 30 Tage kostenlos ausprobieren:Hier erfahren Sie mehrundhier kommen Sie direkt zu allen Artikeln.]
After a 28 days, the test subjects should receive a second, so-called “boost” vaccination with the vaccine based on RNA virus genome.
Quickly – but without compromising security tests
That was a “significant Milestone ”, which had been reached at an“ unprecedented speed, ”said Francis Collins, director of the National Institutes of Health participating in the study. Security aspects would still not be neglected, he emphasized.
[Mehr Informationen zu möglichen Stolpersteinen auf dem Weg zu einem Covid-19-Impfstoff finden Sie hier auf Tagesspiegel-Plus]
It is the first messenger RNA-based vaccine that has ever been tested in a phase III study, said Stéphane Bancel, Managing Director of Moderna, the direct competitor of the Tübingen biotech company Curevac, who also developed a messenger RNA-based vaccine against Covid – 19, but is still in the first phase of testing.
First results on efficacy and safety of the vaccine are “to be expected at the end of the year at the earliest,” said Anthony Fauci, director of the National Institutes of Allergy and Infectious Diseases, “November / December, possibly already in October, but I doubt that. “
[Wenn Sie die wichtigsten Nachrichten aus Berlin, Deutschland und der Welt live auf Ihr Handy haben wollen, empfehlen wir Ihnen unsere runderneuerte App, die Siehier für Apple- und Android-Geräteherunterladen können.]
Moderna is able to produce hundreds of millions of cans by the beginning of next year, said Fauci. Manufacturing capacities are currently being expanded, and efforts are still being made to 2021 deliver a billion doses of the vaccine, said Bancel.
Several expert panels, for example from the National Academy of Medicine, are already dealing with the question of which population groups first – e.g. medical and nursing staff – and which should be vaccinated later said Collins.